I-Sotrovimab, i-antibody ye-monoclonal esele ivunyiwe ukuba iphakathi ukuya kwi-COVID-19 kumazwe amaninzi ifumana imvume yi-MHRA e-UK. Esi sithinteli-mzimba sayilwa ngobukrelekrele ngentsholongwane eguqukayo engqondweni. Ummandla ogcinwe kakhulu weprotein ye-spike wawujoliswe ekucingeni ukuba uguqukile, ngethemba lokulungisa zombini ezidlulileyo kunye nezangoku. hlu kileyo ye-SARS-CoV-2 virus (Omicron) kunye nekamva hlu kileyo, oko bekuya kuba yinto engenakuphepheka.
Xeduvy (sotrovimab), a Umzimba womntu ongena emzimbeni eyenziwe ngentsebenziswano phakathi kwe-GSK kunye ne-Vir Biotechnology esele ivunyiwe kwizigulana ze-COVID-19 ezithambileyo kumazwe aliqela (Ostreliya, eCanada, eU.SA), kutshanje inikwe isigunyaziso sentengiso yi-MHRA, e-UK.1 ukuze isetyenziswe kwizigulana ze-COVID-19 phakathi kweentsuku ezi-5 luqalisile usulelo. Kwafunyaniswa ukuba ikhuselekile kwaye iyasebenza kwaye yanciphisa umngcipheko wokulaliswa esibhedlele nge-79%. Eyona nto iphambili ye-sotrovimab kukuba ijolise kwindawo egcinwe kakhulu ye-spike protein ye-SARS-CoV-2, engenakufane iguquke. Lo mmandla we-SARS-CoV-2 kwabelwana ngawo kunye ne-SARS-CoV-1 (intsholongwane ebangela i-SARS)2, ebonisa ukuba lo mmandla ulondolozwe kakhulu, nto leyo eyenza kube nzima ngakumbi ukuphuhlisa ukuxhathisa. Olu phawu lwenza i-sotrovimab isebenze ngokuchasene nazo zonke hlu kileyo ye-COVID-19 ekhoyo ukuza kuthi ga ngoku, kubandakanywa Micron. Kufuneka kwakhona isebenze nakweliphi na ikamva hlu kileyo ngokunjalo, nje ukuba utshintsho lungenzeki kummandla ogciniweyo3 ye-spike protein ye-SARS-CoV-2, engekabonwa ukuza kuthi ga ngoku.
I-Sotrovimab inokusebenza njengembumbulu yomlingo ngokuchasene nayo yonke into eyaziwayo kunye nekamva elingaziwayo hlu kileyo (ezingaphephekiyo njengoko intsholongwane iqokelela utshintsho oluninzi ngosulelo oluphezulu) lwe-COVID-19. Umgaqo wokuphuhlisa i-sotrovimab ngokujolisa kwingingqi egciniweyo yeprotein ye-spike, inokusetyenziselwa uphuhliso oluthe kratya lwe-antibodies ye-monoclonal kunye nogonyo oluchasene ne-COVID-19.
***
Iingxelo:
- I-GSK 2021. Ushicilelo lweendaba - i-MHRA inika isigunyaziso esinemiqathango sokuthengisa1 kunyango lwe-COVID-19 Xevudy (sotrovimab). Ipapashwe nge-02 kuDisemba 2021. Ifumaneka e https://www.gsk.com/en-gb/media/press-releases/mhra-grants-conditional-marketingauthorisation1-for-covid-19-treatment-xevudy-sotrovimab/
- I-GSK 2021. Ushicilelo lweendaba - Idatha ye-Preclinical ibonisa i-sotrovimab igcina umsebenzi ngokuchasene neenguqu eziphambili ze-Omicron, eyahlukileyo ye-SARS-CoV-2 entsha. Ipapashwe nge-02 kuDisemba 2021. Ifumaneka e https://www.gsk.com/en-gb/media/press-releases/preclinical-data-demonstratesotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/
- Pinto, D., Park, YJ., Beltramello, M. okqhubekayo. Ukunqunyanyiswa kwe-SARS-CoV-2 yi-antibody ye-SARS-CoV yomntu. indalo 583, 290-295 (2020). https://doi.org/10.1038/s41586-020-2349-y
***
